College of Chemistry

We hear a lot about bad air quality in California. And, it’s hard to know what to do about it. But thanks to a 2017 law, two Bay Area communities known for their air pollution are helping set their own air quality policies. But what does putting air pollution in the hands of the people really look like? In this Cross Currents report from KALW, reporter Brett Simpson attends an important community air quality meeting in Richmond as a committee of residents decide how much monitoring they should do before putting stricter standards in place. Richmond, California has some of the worst air pollution in the country. The committee was divided between more monitoring and wanting to enact stricter standards now.

Learn about Martin Head-Gordon, a theoretical chemist at the University of California, Berkeley and Lawrence Berkeley National Laboratory, and a recently elected member of the National Academy of Sciences. He develops electronic structure theory to permit improved calculations of molecules, including the strength of chemical bonds. To better understand how and why bonds form, he also works on energy decomposition analysis (EDA), which gives the value of physically different contributions to chemical bonds.

Alumnus Terry Rosen, the CEO of Arcus Biosciences, and his wife, Tori, have donated $25 million to the College of Chemistry for a building to be named in honor of Terry Rosen’s beloved mentor and former chemistry dean, Clayton Heathcock. Rosen, who obtained his Ph.D. in 1985 while working in Heathcock’s lab, has fond memories of the four years he spent at UC Berkeley and decided that naming a building after Heathcock was a great way to say, ‘Thank you.’

The company, called 4D Molecular Therapeutics Inc., doesn't expect to put its first three experimental single-shot cures for a range of diseases into clinical trials until next year. Yet it already has key partnerships with well-known drug makers Roche, AstraZeneca plc and gene therapy pioneer uniQure NV. Founders David Schaffer, The Hubbard Howe Jr. Distinguished Professor of Biochemical Engineering, and Dr. David Kirn have worked on so-called "viral vectors" — the protein shells ridden by viruses to skip through the body — since before the company was formed in 2013. In gene therapy, those vehicles are engineered to remove the disease-triggering part of a virus and used instead to carry correct versions of genes to replace mutated genes.